1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Drugs for Central Nervous System Diseases Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 Antidepressants 1.2.3 Anxiolytics 1.2.4 Anti-manic 1.2.5 Other 1.3 Market by Application 1.3.1 Global Drugs for Central Nervous System Diseases Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 Hospital Pharmacies 1.3.3 Retail Pharmacies 1.3.4 Online Pharmacies 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Drugs for Central Nervous System Diseases Market Perspective (2016-2027) 2.2 Drugs for Central Nervous System Diseases Growth Trends by Regions 2.2.1 Drugs for Central Nervous System Diseases Market Size by Regions: 2016 VS 2021 VS 2027 2.2.2 Drugs for Central Nervous System Diseases Historic Market Share by Regions (2016-2021) 2.2.3 Drugs for Central Nervous System Diseases Forecasted Market Size by Regions (2022-2027) 2.3 Drugs for Central Nervous System Diseases Industry Dynamic 2.3.1 Drugs for Central Nervous System Diseases Market Trends 2.3.2 Drugs for Central Nervous System Diseases Market Drivers 2.3.3 Drugs for Central Nervous System Diseases Market Challenges 2.3.4 Drugs for Central Nervous System Diseases Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Drugs for Central Nervous System Diseases Players by Revenue 3.1.1 Global Top Drugs for Central Nervous System Diseases Players by Revenue (2016-2021) 3.1.2 Global Drugs for Central Nervous System Diseases Revenue Market Share by Players (2016-2021) 3.2 Global Drugs for Central Nervous System Diseases Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by Drugs for Central Nervous System Diseases Revenue 3.4 Global Drugs for Central Nervous System Diseases Market Concentration Ratio 3.4.1 Global Drugs for Central Nervous System Diseases Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Drugs for Central Nervous System Diseases Revenue in 2020 3.5 Drugs for Central Nervous System Diseases Key Players Head office and Area Served 3.6 Key Players Drugs for Central Nervous System Diseases Product Solution and Service 3.7 Date of Enter into Drugs for Central Nervous System Diseases Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Drugs for Central Nervous System Diseases Breakdown Data by Type 4.1 Global Drugs for Central Nervous System Diseases Historic Market Size by Type (2016-2021) 4.2 Global Drugs for Central Nervous System Diseases Forecasted Market Size by Type (2022-2027) 5 Drugs for Central Nervous System Diseases Breakdown Data by Application 5.1 Global Drugs for Central Nervous System Diseases Historic Market Size by Application (2016-2021) 5.2 Global Drugs for Central Nervous System Diseases Forecasted Market Size by Application (2022-2027) 6 North America 6.1 North America Drugs for Central Nervous System Diseases Market Size (2016-2027) 6.2 North America Drugs for Central Nervous System Diseases Market Size by Type 6.2.1 North America Drugs for Central Nervous System Diseases Market Size by Type (2016-2021) 6.2.2 North America Drugs for Central Nervous System Diseases Market Size by Type (2022-2027) 6.2.3 North America Drugs for Central Nervous System Diseases Market Size by Type (2016-2027) 6.3 North America Drugs for Central Nervous System Diseases Market Size by Application 6.3.1 North America Drugs for Central Nervous System Diseases Market Size by Application (2016-2021) 6.3.2 North America Drugs for Central Nervous System Diseases Market Size by Application (2022-2027) 6.3.3 North America Drugs for Central Nervous System Diseases Market Size by Application (2016-2027) 6.4 North America Drugs for Central Nervous System Diseases Market Size by Country 6.4.1 North America Drugs for Central Nervous System Diseases Market Size by Country (2016-2021) 6.4.2 North America Drugs for Central Nervous System Diseases Market Size by Country (2022-2027) 6.4.3 United States 6.4.4 Canada 7 Europe 7.1 Europe Drugs for Central Nervous System Diseases Market Size (2016-2027) 7.2 Europe Drugs for Central Nervous System Diseases Market Size by Type 7.2.1 Europe Drugs for Central Nervous System Diseases Market Size by Type (2016-2021) 7.2.2 Europe Drugs for Central Nervous System Diseases Market Size by Type (2022-2027) 7.2.3 Europe Drugs for Central Nervous System Diseases Market Size by Type (2016-2027) 7.3 Europe Drugs for Central Nervous System Diseases Market Size by Application 7.3.1 Europe Drugs for Central Nervous System Diseases Market Size by Application (2016-2021) 7.3.2 Europe Drugs for Central Nervous System Diseases Market Size by Application (2022-2027) 7.3.3 Europe Drugs for Central Nervous System Diseases Market Size by Application (2016-2027) 7.4 Europe Drugs for Central Nervous System Diseases Market Size by Country 7.4.1 Europe Drugs for Central Nervous System Diseases Market Size by Country (2016-2021) 7.4.2 Europe Drugs for Central Nervous System Diseases Market Size by Country (2022-2027) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic 8 Asia-Pacific 8.1 Asia-Pacific Drugs for Central Nervous System Diseases Market Size (2016-2027) 8.2 Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Type 8.2.1 Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Type (2016-2021) 8.2.2 Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Type (2022-2027) 8.2.3 Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Type (2016-2027) 8.3 Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Application 8.3.1 Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Application (2016-2021) 8.3.2 Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Application (2022-2027) 8.3.3 Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Application (2016-2027) 8.4 Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Region 8.4.1 Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Region (2016-2021) 8.4.2 Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Region (2022-2027) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Drugs for Central Nervous System Diseases Market Size (2016-2027) 9.2 Latin America Drugs for Central Nervous System Diseases Market Size by Type 9.2.1 Latin America Drugs for Central Nervous System Diseases Market Size by Type (2016-2021) 9.2.2 Latin America Drugs for Central Nervous System Diseases Market Size by Type (2022-2027) 9.2.3 Latin America Drugs for Central Nervous System Diseases Market Size by Type (2016-2027) 9.3 Latin America Drugs for Central Nervous System Diseases Market Size by Application 9.3.1 Latin America Drugs for Central Nervous System Diseases Market Size by Application (2016-2021) 9.3.2 Latin America Drugs for Central Nervous System Diseases Market Size by Application (2022-2027) 9.3.3 Latin America Drugs for Central Nervous System Diseases Market Size by Application (2016-2027) 9.4 Latin America Drugs for Central Nervous System Diseases Market Size by Country 9.4.1 Latin America Drugs for Central Nervous System Diseases Market Size by Country (2016-2021) 9.4.2 Latin America Drugs for Central Nervous System Diseases Market Size by Country (2022-2027) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Drugs for Central Nervous System Diseases Market Size (2016-2027) 10.2 Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Type 10.2.1 Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Type (2016-2021) 10.2.2 Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Type (2022-2027) 10.2.3 Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Type (2016-2027) 10.3 Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Application 10.3.1 Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Application (2016-2021) 10.3.2 Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Application (2022-2027) 10.3.3 Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Application (2016-2027) 10.4 Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Country 10.4.1 Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Country (2016-2021) 10.4.2 Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Country (2022-2027) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 Alkermes 11.1.1 Alkermes Company Details 11.1.2 Alkermes Business Overview 11.1.3 Alkermes Drugs for Central Nervous System Diseases Introduction 11.1.4 Alkermes Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) 11.1.5 Alkermes Recent Development 11.2 Astrazeneca 11.2.1 Astrazeneca Company Details 11.2.2 Astrazeneca Business Overview 11.2.3 Astrazeneca Drugs for Central Nervous System Diseases Introduction 11.2.4 Astrazeneca Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) 11.2.5 Astrazeneca Recent Development 11.3 Biogen 11.3.1 Biogen Company Details 11.3.2 Biogen Business Overview 11.3.3 Biogen Drugs for Central Nervous System Diseases Introduction 11.3.4 Biogen Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) 11.3.5 Biogen Recent Development 11.4 Bristol Myers Squibb 11.4.1 Bristol Myers Squibb Company Details 11.4.2 Bristol Myers Squibb Business Overview 11.4.3 Bristol Myers Squibb Drugs for Central Nervous System Diseases Introduction 11.4.4 Bristol Myers Squibb Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) 11.4.5 Bristol Myers Squibb Recent Development 11.5 Lilly 11.5.1 Lilly Company Details 11.5.2 Lilly Business Overview 11.5.3 Lilly Drugs for Central Nervous System Diseases Introduction 11.5.4 Lilly Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) 11.5.5 Lilly Recent Development 11.6 GSK 11.6.1 GSK Company Details 11.6.2 GSK Business Overview 11.6.3 GSK Drugs for Central Nervous System Diseases Introduction 11.6.4 GSK Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) 11.6.5 GSK Recent Development 11.7 Merck 11.7.1 Merck Company Details 11.7.2 Merck Business Overview 11.7.3 Merck Drugs for Central Nervous System Diseases Introduction 11.7.4 Merck Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) 11.7.5 Merck Recent Development 11.8 Sunovion Pharmaceuticals 11.8.1 Sunovion Pharmaceuticals Company Details 11.8.2 Sunovion Pharmaceuticals Business Overview 11.8.3 Sunovion Pharmaceuticals Drugs for Central Nervous System Diseases Introduction 11.8.4 Sunovion Pharmaceuticals Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) 11.8.5 Sunovion Pharmaceuticals Recent Development 11.9 Pfizer 11.9.1 Pfizer Company Details 11.9.2 Pfizer Business Overview 11.9.3 Pfizer Drugs for Central Nervous System Diseases Introduction 11.9.4 Pfizer Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) 11.9.5 Pfizer Recent Development 11.10 Teva 11.10.1 Teva Company Details 11.10.2 Teva Business Overview 11.10.3 Teva Drugs for Central Nervous System Diseases Introduction 11.10.4 Teva Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) 11.10.5 Teva Recent Development 11.11 Norvatis 11.11.1 Norvatis Company Details 11.11.2 Norvatis Business Overview 11.11.3 Norvatis Drugs for Central Nervous System Diseases Introduction 11.11.4 Norvatis Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) 11.11.5 Norvatis Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Drugs for Central Nervous System Diseases Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027 Table 2. Key Players of Antidepressants Table 3. Key Players of Anxiolytics Table 4. Key Players of Anti-manic Table 5. Key Players of Other Table 6. Global Drugs for Central Nervous System Diseases Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027 Table 7. Global Drugs for Central Nervous System Diseases Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027 Table 8. Global Drugs for Central Nervous System Diseases Market Size by Regions (2016-2021) & (US$ Million) Table 9. Global Drugs for Central Nervous System Diseases Market Share by Regions (2016-2021) Table 10. Global Drugs for Central Nervous System Diseases Forecasted Market Size by Regions (2022-2027) & (US$ Million) Table 11. Global Drugs for Central Nervous System Diseases Market Share by Regions (2022-2027) Table 12. Drugs for Central Nervous System Diseases Market Trends Table 13. Drugs for Central Nervous System Diseases Market Drivers Table 14. Drugs for Central Nervous System Diseases Market Challenges Table 15. Drugs for Central Nervous System Diseases Market Restraints Table 16. Global Drugs for Central Nervous System Diseases Revenue by Players (2016-2021) & (US$ Million) Table 17. Global Drugs for Central Nervous System Diseases Market Share by Players (2016-2021) Table 18. Global Top Drugs for Central Nervous System Diseases Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Central Nervous System Diseases as of 2020) Table 19. Ranking of Global Top Drugs for Central Nervous System Diseases Companies by Revenue (US$ Million) in 2020 Table 20. Global 5 Largest Players Market Share by Drugs for Central Nervous System Diseases Revenue (CR5 and HHI) & (2016-2021) Table 21. Key Players Headquarters and Area Served Table 22. Key Players Drugs for Central Nervous System Diseases Product Solution and Service Table 23. Date of Enter into Drugs for Central Nervous System Diseases Market Table 24. Mergers & Acquisitions, Expansion Plans Table 25. Global Drugs for Central Nervous System Diseases Market Size by Type (2016-2021) (US$ Million) Table 26. Global Drugs for Central Nervous System Diseases Revenue Market Share by Type (2016-2021) Table 27. Global Drugs for Central Nervous System Diseases Forecasted Market Size by Type (2022-2027) (US$ Million) Table 28. Global Drugs for Central Nervous System Diseases Revenue Market Share by Type (2022-2027) & (US$ Million) Table 29. Global Drugs for Central Nervous System Diseases Market Size Share by Application (2016-2021) & (US$ Million) Table 30. Global Drugs for Central Nervous System Diseases Revenue Market Share by Application (2016-2021) Table 31. Global Drugs for Central Nervous System Diseases Forecasted Market Size by Application (2022-2027) (US$ Million) Table 32. Global Drugs for Central Nervous System Diseases Revenue Market Share by Application (2022-2027) & (US$ Million) Table 33. North America Drugs for Central Nervous System Diseases Market Size by Type (2016-2021) (US$ Million) Table 34. North America Drugs for Central Nervous System Diseases Market Size by Type (2022-2027) & (US$ Million) Table 35. North America Drugs for Central Nervous System Diseases Market Size by Application (2016-2021) (US$ Million) Table 36. North America Drugs for Central Nervous System Diseases Market Size by Application (2022-2027) & (US$ Million) Table 37. North America Drugs for Central Nervous System Diseases Market Size by Country (2016-2021) & (US$ Million) Table 38. North America Drugs for Central Nervous System Diseases Market Size by Country (2022-2027) & (US$ Million) Table 39. Europe Drugs for Central Nervous System Diseases Market Size by Type (2016-2021) (US$ Million) Table 40. Europe Drugs for Central Nervous System Diseases Market Size by Type (2022-2027) & (US$ Million) Table 41. Europe Drugs for Central Nervous System Diseases Market Size by Application (2016-2021) (US$ Million) Table 42. Europe Drugs for Central Nervous System Diseases Market Size by Application (2022-2027) & (US$ Million) Table 43. Europe Drugs for Central Nervous System Diseases Market Size by Country (2016-2021) & (US$ Million) Table 44. Europe Drugs for Central Nervous System Diseases Market Size by Country (2022-2027) & (US$ Million) Table 45. Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Type (2016-2021) (US$ Million) Table 46. Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Type (2022-2027) & (US$ Million) Table 47. Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Application (2016-2021) (US$ Million) Table 48. Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Application (2022-2027) & (US$ Million) Table 49. Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Region (2016-2021) & (US$ Million) Table 50. Asia-Pacific Drugs for Central Nervous System Diseases Market Size by Region (2022-2027) & (US$ Million) Table 51. Latin America Drugs for Central Nervous System Diseases Market Size by Type (2016-2021) (US$ Million) Table 52. Latin America Drugs for Central Nervous System Diseases Market Size by Type (2022-2027) & (US$ Million) Table 53. Latin America Drugs for Central Nervous System Diseases Market Size by Application (2016-2021) (US$ Million) Table 54. Latin America Drugs for Central Nervous System Diseases Market Size by Application (2022-2027) & (US$ Million) Table 55. Latin America Drugs for Central Nervous System Diseases Market Size by Country (2016-2021) & (US$ Million) Table 56. Latin America Drugs for Central Nervous System Diseases Market Size by Country (2022-2027) & (US$ Million) Table 57. Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Type (2016-2021) (US$ Million) Table 58. Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Type (2022-2027) & (US$ Million) Table 59. Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Application (2016-2021) (US$ Million) Table 60. Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Application (2022-2027) & (US$ Million) Table 61. Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Country (2016-2021) & (US$ Million) Table 62. Middle East & Africa Drugs for Central Nervous System Diseases Market Size by Country (2022-2027) & (US$ Million) Table 63. Alkermes Company Details Table 64. Alkermes Business Overview Table 65. Alkermes Drugs for Central Nervous System Diseases Product Table 66. Alkermes Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) & (US$ Million) Table 67. Alkermes Recent Development Table 68. Astrazeneca Company Details Table 69. Astrazeneca Business Overview Table 70. Astrazeneca Drugs for Central Nervous System Diseases Product Table 71. Astrazeneca Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) & (US$ Million) Table 72. Astrazeneca Recent Development Table 73. Biogen Company Details Table 74. Biogen Business Overview Table 75. Biogen Drugs for Central Nervous System Diseases Product Table 76. Biogen Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) & (US$ Million) Table 77. Biogen Recent Development Table 78. Bristol Myers Squibb Company Details Table 79. Bristol Myers Squibb Business Overview Table 80. Bristol Myers Squibb Drugs for Central Nervous System Diseases Product Table 81. Bristol Myers Squibb Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) & (US$ Million) Table 82. Bristol Myers Squibb Recent Development Table 83. Lilly Company Details Table 84. Lilly Business Overview Table 85. Lilly Drugs for Central Nervous System Diseases Product Table 86. Lilly Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) & (US$ Million) Table 87. Lilly Recent Development Table 88. GSK Company Details Table 89. GSK Business Overview Table 90. GSK Drugs for Central Nervous System Diseases Product Table 91. GSK Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) & (US$ Million) Table 92. GSK Recent Development Table 93. Merck Company Details Table 94. Merck Business Overview Table 95. Merck Drugs for Central Nervous System Diseases Product Table 96. Merck Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) & (US$ Million) Table 97. Merck Recent Development Table 98. Sunovion Pharmaceuticals Company Details Table 99. Sunovion Pharmaceuticals Business Overview Table 100. Sunovion Pharmaceuticals Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) & (US$ Million) Table 101. Sunovion Pharmaceuticals Recent Development Table 102. Pfizer Company Details Table 103. Pfizer Business Overview Table 104. Pfizer Drugs for Central Nervous System Diseases Product Table 105. Pfizer Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) & (US$ Million) Table 106. Pfizer Recent Development Table 107. Teva Company Details Table 108. Teva Business Overview Table 109. Teva Drugs for Central Nervous System Diseases Product Table 110. Teva Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) & (US$ Million) Table 111. Teva Recent Development Table 112. Norvatis Company Details Table 113. Norvatis Business Overview Table 114. Norvatis Drugs for Central Nervous System Diseases Product Table 115. Norvatis Revenue in Drugs for Central Nervous System Diseases Business (2016-2021) & (US$ Million) Table 116. Norvatis Recent Development Table 117. Research Programs/Design for This Report Table 118. Key Data Information from Secondary Sources Table 119. Key Data Information from Primary Sources List of Figures Figure 1. Global Drugs for Central Nervous System Diseases Market Share by Type: 2020 VS 2027 Figure 2. Antidepressants Features Figure 3. Anxiolytics Features Figure 4. Anti-manic Features Figure 5. Other Features Figure 6. Global Drugs for Central Nervous System Diseases Market Share by Application: 2020 VS 2027 Figure 7. Hospital Pharmacies Case Studies Figure 8. Retail Pharmacies Case Studies Figure 9. Online Pharmacies Case Studies Figure 10. Drugs for Central Nervous System Diseases Report Years Considered Figure 11. Global Drugs for Central Nervous System Diseases Market Size (US$ Million), Year-over-Year: 2016-2027 Figure 12. Global Drugs for Central Nervous System Diseases Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 13. Global Drugs for Central Nervous System Diseases Market Share by Regions: 2020 VS 2027 Figure 14. Global Drugs for Central Nervous System Diseases Market Share by Regions (2022-2027) Figure 15. Global Drugs for Central Nervous System Diseases Market Share by Players in 2020 Figure 16. Global Top Drugs for Central Nervous System Diseases Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Central Nervous System Diseases as of 2020 Figure 17. The Top 10 and 5 Players Market Share by Drugs for Central Nervous System Diseases Revenue in 2020 Figure 18. Global Drugs for Central Nervous System Diseases Revenue Market Share by Type (2016-2021) Figure 19. Global Drugs for Central Nervous System Diseases Revenue Market Share by Type (2022-2027) Figure 20. North America Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 21. North America Drugs for Central Nervous System Diseases Market Share by Type (2016-2027) Figure 22. North America Drugs for Central Nervous System Diseases Market Share by Application (2016-2027) Figure 23. North America Drugs for Central Nervous System Diseases Market Share by Country (2016-2027) Figure 24. United States Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 25. Canada Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 26. Europe Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 27. Europe Drugs for Central Nervous System Diseases Market Share by Type (2016-2027) Figure 28. Europe Drugs for Central Nervous System Diseases Market Share by Application (2016-2027) Figure 29. Europe Drugs for Central Nervous System Diseases Market Share by Country (2016-2027) Figure 30. Germany Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 31. France Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 32. U.K. Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 33. Italy Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 34. Russia Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 35. Nordic Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 36. Asia-Pacific Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 37. Asia-Pacific Drugs for Central Nervous System Diseases Market Share by Type (2016-2027) Figure 38. Asia-Pacific Drugs for Central Nervous System Diseases Market Share by Application (2016-2027) Figure 39. Asia-Pacific Drugs for Central Nervous System Diseases Market Share by Region (2016-2027) Figure 40. China Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 41. Japan Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 42. South Korea Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 43. Southeast Asia Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 44. India Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 45. Australia Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 46. Latin America Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 47. Latin America Drugs for Central Nervous System Diseases Market Share by Type (2016-2027) Figure 48. Latin America Drugs for Central Nervous System Diseases Market Share by Application (2016-2027) Figure 49. Latin America Drugs for Central Nervous System Diseases Market Share by Country (2016-2027) Figure 50. Mexico Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 51. Brazil Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 52. Middle East & Africa Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 53. Middle East & Africa Drugs for Central Nervous System Diseases Market Share by Type (2016-2027) Figure 54. Middle East & Africa Drugs for Central Nervous System Diseases Market Share by Application (2016-2027) Figure 55. Middle East & Africa Drugs for Central Nervous System Diseases Market Share by Country (2016-2027) Figure 56. Turkey Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 57. Saudi Arabia Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 58. UAE Drugs for Central Nervous System Diseases Market Size YoY Growth (2016-2027) & (US$ Million) Figure 59. Alkermes Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2016-2021) Figure 60. Astrazeneca Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2016-2021) Figure 61. Biogen Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2016-2021) Figure 62. Bristol Myers Squibb Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2016-2021) Figure 63. Lilly Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2016-2021) Figure 64. GSK Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2016-2021) Figure 65. Merck Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2016-2021) Figure 66. Sunovion Pharmaceuticals Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2016-2021) Figure 67. Pfizer Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2016-2021) Figure 68. Teva Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2016-2021) Figure 69. Norvatis Revenue Growth Rate in Drugs for Central Nervous System Diseases Business (2016-2021) Figure 70. Bottom-up and Top-down Approaches for This Report Figure 71. Data Triangulation Figure 72. Key Executives Interviewed